Intersect ENT (XENT) Tops Q3 EPS by 4c

Intersect ENT (NASDAQ: XENT) reported Q3 EPS of ($0.15), $0.04 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $22.3 million versus the consensus estimate of $21.51 million.

Outlook

The company’s revenue outlook for the fourth quarter 2017 is in the range of $27.3 to $27.8 million and for the full year in the range of $94.1-$94.6 million. The outlook for 2017 gross margin continues to be approximately 84%. The company’s forecast for 2017 operating expenses, including the addition of pre-approval production of SINUVA, which would generate incremental R&D expense of approximately $1.5 million, is in the range of $98-$100 million.

For earnings history and earnings-related data on Intersect ENT (XENT) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• KULR Technology Group (KULR) Misses Q2 EPS by 39c
• Assembly Biosciences (ASMB) Tops Q2 EPS by 53c